Hemorrhagic Proctocolitis Clinical Trials

Find Hemorrhagic Proctocolitis Clinical Trials Near You

The Effect of Non-Nutritive Food Sweeteners in Inflammatory Bowel Disease

Status: Recruiting
Location: See all (3) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study will focus on the commonly used non-nutritive sweetener (NNS) sucralose (2 sachets/day resulting in daily dose: sucralose 2.5mg/kg) and its role in changing the gut microbiota in humans with IBD, compared to healthy non-IBD individuals. We will focus on studying IBD patients affected with CD as a proof of principle that could be tested later in other IBD subtype (ulcerative colitis or others specific surgical conditions).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: t
View:

• Age range from: 18 to 70 years. Male or female. Documented diagnosis of Crohns disease. CD outpatients in remission; Harvey Bradshaw- index in remission (\<6 score).

• Capable of providing consent to participate. Able to complete daily surveys and take oral nutrition. Able to record meal intake. Healthy controls with no diagnosis of IBD or Irritable Bowel Syndrome (IBS).

Locations
United States
Ohio
UH Minoff Health Center
RECRUITING
Chagrin Falls
University Hospitals Cleveland Medical Center
RECRUITING
Cleveland
UH Westlake Health Center
RECRUITING
Westlake
Contact Information
Primary
Abigail Raffner, RD PhD
Abigail.Raffner@uhhospitals.org
216-327-6003
Backup
Sargun Singh, M.B.B.S.
sargun.singh@uhhospitals.org
216-333-6085
Time Frame
Start Date: 2025-02-03
Estimated Completion Date: 2026-12
Participants
Target number of participants: 40
Treatments
Experimental: Crohn's participants
Crohn's participants will consume artificial sweetener: sucralose
Experimental: Healthy Controls
Healthy control participants will consume artificial sweetener: sucralose
Sponsors
Leads: University Hospitals Cleveland Medical Center
Collaborators: Crohn's and Colitis Foundation

This content was sourced from clinicaltrials.gov